



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Benufutamab

Cat. No.:	HY-P99470
CAS No.:	2109730-69-8
Target:	TNF Receptor; Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects ^[1] .									
In Vitro	<p>Benufutamab (GEN1029; HexaBody-DR5/DR5; 20 µg/mL; 24 hours) induces potent cytotoxicity in multiple myeloma (MM) cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Multiple myeloma (MM) cells</td> </tr> <tr> <td>Concentration:</td> <td>20 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Induced potent cytotoxicity.</td> </tr> </table>		Cell Line:	Multiple myeloma (MM) cells	Concentration:	20 µg/mL	Incubation Time:	24 hours	Result:	Induced potent cytotoxicity.
Cell Line:	Multiple myeloma (MM) cells									
Concentration:	20 µg/mL									
Incubation Time:	24 hours									
Result:	Induced potent cytotoxicity.									
In Vivo	<p>Benufutamab (GEN1029; HexaBody-DR5/DR5; 0.5-2 mg/kg; i.p.; once a week; for 9 weeks) shows significant antitumor activity in PDX models for colorectal cancer^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells^[2]</td> </tr> <tr> <td>Dosage:</td> <td>0.5 mg/kg, or 2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; once a week; for 9 weeks</td> </tr> <tr> <td>Result:</td> <td>Showed significant antitumor activity.</td> </tr> </table>		Animal Model:	Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells ^[2]	Dosage:	0.5 mg/kg, or 2 mg/kg	Administration:	i.p.; once a week; for 9 weeks	Result:	Showed significant antitumor activity.
Animal Model:	Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells ^[2]									
Dosage:	0.5 mg/kg, or 2 mg/kg									
Administration:	i.p.; once a week; for 9 weeks									
Result:	Showed significant antitumor activity.									

REFERENCES

[1]. Hilma J van der Horst, et al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2165-2172.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA